J
24.05
-1.07 (-4.26%)
| Previous Close | 25.12 |
| Open | 24.91 |
| Volume | 487,162 |
| Avg. Volume (3M) | 777,312 |
| Market Cap | 1,445,258,240 |
| Price / Sales | 3.14 |
| Price / Book | 1.42 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -1,216.61% |
| Diluted EPS (TTM) | -1.36 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 2.23% |
| Current Ratio (MRQ) | 58.47 |
| Operating Cash Flow (TTM) | -46.00 M |
| Levered Free Cash Flow (TTM) | -27.01 M |
| Return on Assets (TTM) | -8.16% |
| Return on Equity (TTM) | -9.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Janux Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
-0.1
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.0 |
| Average | -0.13 |
|
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 6.69% |
| % Held by Institutions | 113.78% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 100.00 (Truist Securities, 315.80%) | Buy |
| Median | 56.00 (132.85%) | |
| Low | 42.00 (Piper Sandler, 74.64%) | Buy |
| Average | 61.83 (157.09%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 24.31 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 17 Sep 2025 | 47.00 (95.43%) | Buy | 23.46 |
| Stifel | 10 Sep 2025 | 45.00 (87.11%) | Buy | 24.31 |
| Truist Securities | 10 Sep 2025 | 100.00 (315.80%) | Buy | 24.31 |
| Guggenheim | 04 Sep 2025 | 72.00 (199.38%) | Buy | 23.94 |
| Piper Sandler | 19 Aug 2025 | 42.00 (74.64%) | Buy | 24.70 |
| Raymond James | 11 Jul 2025 | 65.00 (170.27%) | Buy | 25.15 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Aug 2025 | Announcement | Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights |
| 24 Jul 2025 | Announcement | Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day |
| 17 Jul 2025 | Announcement | Janux Therapeutics to Host Virtual R&D Day on July 24, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |